Traders Buy Large Volume of Oncology Institute Call Options (NASDAQ:TOI)

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of unusually large options trading on Thursday. Investors purchased 25,717 call options on the stock. This is an increase of 2,397% compared to the typical volume of 1,030 call options.

Wall Street Analyst Weigh In

Several research analysts have issued reports on TOI shares. Weiss Ratings restated a “sell (d-)” rating on shares of Oncology Institute in a report on Monday, April 20th. BTIG Research upped their price objective on shares of Oncology Institute from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday. Lake Street Capital initiated coverage on shares of Oncology Institute in a research report on Monday, July 6th. They set a “buy” rating and a $10.00 price objective for the company. B. Riley Financial lifted their target price on shares of Oncology Institute from $6.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Finally, Needham & Company LLC boosted their target price on shares of Oncology Institute from $5.00 to $7.00 and gave the company a “buy” rating in a report on Wednesday, June 17th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.40.

Insiders Place Their Bets

In other Oncology Institute news, Director Mohit Kaushal sold 57,286 shares of Oncology Institute stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.50, for a total transaction of $200,501.00. Following the transaction, the director directly owned 211,016 shares of the company’s stock, valued at approximately $738,556. The trade was a 21.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Yale Podnos sold 23,451 shares of the stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $5.38, for a total value of $126,166.38. Following the completion of the sale, the insider directly owned 259,527 shares of the company’s stock, valued at approximately $1,396,255.26. The trade was a 8.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have purchased 98,500 shares of company stock valued at $426,655 and have sold 119,170 shares valued at $461,183. Company insiders own 4.40% of the company’s stock.

Institutional Investors Weigh In On Oncology Institute

A number of large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC bought a new stake in Oncology Institute in the fourth quarter valued at $31,000. Pekin Hardy Strauss Inc. bought a new position in shares of Oncology Institute during the 4th quarter worth about $36,000. Cetera Investment Advisers boosted its position in shares of Oncology Institute by 35.0% during the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company’s stock worth $36,000 after purchasing an additional 4,545 shares in the last quarter. State of Wyoming acquired a new stake in shares of Oncology Institute in the 2nd quarter valued at about $37,000. Finally, R Squared Ltd acquired a new stake in shares of Oncology Institute in the 4th quarter valued at about $41,000. 36.86% of the stock is currently owned by institutional investors and hedge funds.

Oncology Institute Trading Up 0.7%

NASDAQ TOI traded up $0.04 during trading hours on Friday, hitting $5.89. 3,929,311 shares of the company’s stock were exchanged, compared to its average volume of 1,743,573. The firm has a market cap of $582.17 million, a price-to-earnings ratio of -15.92 and a beta of 0.36. The stock has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $3.74. Oncology Institute has a 1-year low of $2.32 and a 1-year high of $6.11.

Oncology Institute (NASDAQ:TOI) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.05. The business had revenue of $147.44 million for the quarter, compared to the consensus estimate of $142.10 million. On average, sell-side analysts anticipate that Oncology Institute will post -0.17 earnings per share for the current fiscal year.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.